Innovative Pulsed Electric Field Therapy Offers New Hope in Lung Cancer

In a significant advancement for thoracic oncology, WVU Medicine has become the first health care system in West Virginia to implement pulsed electric field (PEF) therapy for metastatic lung nodules. Led by specialists at the WVU Heart and Vascular Institute (HVI), this innovative approach provides a vital new line of defense for patients with advanced malignancies that have become resistant to standard systemic treatments.

Saiesh Reddy Voppuru, MD, a thoracic surgeon at WVU Medicine, explains that PEF represents a paradigm shift from traditional ablation. Unlike radiofrequency ablation or cryoablation, which use extreme heat or cold, PEF is a nonthermal technique. It utilizes irreversible electroporation—high-voltage electric currents—to create microscopic pores in cancer cell membranes, inducing cell death without damaging adjacent vital structures like airways or blood vessels. This precision is particularly critical in the delicate environment of the lungs.

For patients with stage IV disease, the clinical objective often shifts from eradication to managing the cancer as a chronic condition. While chemotherapy and immunotherapy remain the standard of care, many patients eventually exhaust these options. PEF therapy offers a unique physiological advantage here; beyond local destruction, it is believed to induce both localized and systemic immune responses. By "priming" the immune system, PEF may bolster the efficacy of subsequent lines of systemic therapy, helping to stabilize the disease and prevent further progression.

The integration of PEF is further enhanced by robotic-assisted technology. At WVU Medicine, surgeons utilize robotic bronchoscopy to navigate the lung's complex pathways, reaching difficult peripheral nodules with high precision. To further validate this modality, the institution is participating in the PROPEL registry, a multicenter trial tracking patient outcomes. Looking ahead, researchers hope to expand PEF's applications to early-stage disease, potentially offering a noninvasive alternative to surgery or radiation.

Read the full interview with Dr Voppuru here.